SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 657.80+1.7%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: A.J. Mullen who wrote (3198)1/9/2021 4:24:18 PM
From: A.J. Mullen   of 3557
 
From the same preprint: Compared with control, median adjusted odds ratios for hospital survival were 1.64 (95%CrI 1.14, 2.35) for tocilizumab and 2.01 (95% CrI 1.18, 4.71) for sarilumab, yielding 99.6% and 99.5% posterior probabilities of superiority. That was using a model incorporating many variable among patients and their treatments. Again, sarilumab seems to improve the odds more than tocilizumab.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News